{"id":"NCT01774786","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer","officialTitle":"A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-10","primaryCompletion":"2016-12-09","completion":"2019-12-31","firstPosted":"2013-01-24","resultsPosted":"2018-02-14","lastUpdate":"2020-12-30"},"enrollment":780,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer"],"interventions":[{"type":"DRUG","name":"5-Fluorouracil","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":["Perjeta","RO4368451"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin","RO0452317"]}],"arms":[{"label":"Pertuzumab + Trastuzumab + Chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo + Trastuzumab + Chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line treatment in participants with HER2-positive metastatic gastroesophageal junction (GEJ) or gastric cancer (GC). Participants will be randomized to receive pertuzumab 840 milligrams (mg) or placebo intravenously every 3 weeks (q3w) in combination with trastuzumab (initial dose of 8 milligrams per kilogram \\[mg/kg\\] intravenously \\[IV\\] followed by 6 mg/kg IV q3w) and cisplatin and fluoropyrimidine (capecitabine or 5-fluorouracil) for the first 6 treatment cycles. Participants will continue to receive pertuzumab or placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months)","effectByArm":[{"arm":"Pertuzumab + Trastuzumab + Chemotherapy","deltaMin":17.5,"sd":null},{"arm":"Placebo + Trastuzumab + Chemotherapy","deltaMin":14.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0565"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":172,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Croatia","El Salvador","Finland","Germany","Guatemala","Hungary","Italy","Japan","Kazakhstan","Malaysia","Mexico","Netherlands","North Macedonia","Panama","Peru","Poland","Romania","Russia","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["36066725","31234927","31183514","30217672"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":178,"n":385},"commonTop":["Nausea","Neutropenia","Diarrhoea","Decreased appetite","Anaemia"]}}